Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 4, 2022- New U.S. FDA-approved labeling lifts restrictions on 60-centimeter Octrode™ leads, which are implanted, electrically insulated wires that transmit electrical impulses to the target nerves- Expanded MRI compatibility allows more patients to obtain necessary scans and increases efficiencies for radiologists
- Nov 15, 2021- Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity
- Nov 12, 2021-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval
-
Nov 10, 2021- One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care